-
EP4259201
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4259201
| EP4259201 - ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.09.2023 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 17.06.2022 | Most recent event Tooltip | 12.10.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 / US | For all designated states Tri-Institutional Therapeutics Discovery Institute, Inc. Belfer Research Building 413 East 69th Street, 16th Floor, Box 300 New York NY 10021 / US | [2023/42] | Inventor(s) | 01 /
SPRIGGS, David New York, New York 10065 / US | 02 /
THAPI, Dharmarao New York, New York 10065 / US | 03 /
LORENZ, Ivo C. New York, New York 10021 / US | 04 /
WHITE, Thomas E. New York, New York 10021 / US | [2023/42] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham, West Midlands B16 8QQ / GB | [2023/42] | Application number, filing date | 21904210.8 | 07.12.2021 | [2023/42] | WO2021US62099 | Priority number, date | US202063122714P | 08.12.2020 Original published format: US 202063122714 P | [2023/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022125482 | Date: | 16.06.2022 | Language: | EN | [2022/24] | Type: | A1 Application with search report | No.: | EP4259201 | Date: | 18.10.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.06.2022 takes the place of the publication of the European patent application. | [2023/42] | Search report(s) | International search report - published on: | US | 16.06.2022 | Classification | IPC: | C07K16/28, A61K39/395, A61K39/44, A61K49/16, A61K39/00, A61P35/00 | [2024/46] | CPC: |
C07K16/2851 (EP,US);
A61K47/6849 (US);
A61K49/0002 (US);
A61P35/00 (EP,US);
C07K16/2809 (US);
C07K2317/21 (EP,US);
C07K2317/24 (EP,US);
C07K2317/31 (EP,US);
C07K2317/622 (EP,US);
C07K2317/92 (EP)
(-)
|
| Former IPC [2023/42] | A61K39/395, A61K39/44, A61K49/16 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/42] | Title | German: | ANTIKÖRPER GEGEN GALECTIN-3 UND VERFAHREN ZUR VERWENDUNG DAVON | [2023/42] | English: | ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF | [2023/42] | French: | ANTICORPS DIRIGÉS CONTRE LA GALECTINE-3 ET LEURS MÉTHODES D'UTILISATION | [2023/42] | Entry into regional phase | 30.06.2023 | National basic fee paid | 30.06.2023 | Search fee paid | 30.06.2023 | Designation fee(s) paid | 30.06.2023 | Examination fee paid | Examination procedure | 30.06.2023 | Examination requested [2023/42] | 26.01.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 30.06.2023 | Renewal fee patent year 03 | 11.10.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2014160499 (CREATICS LLC [US]); | [A]WO2016073906 (SCHOLAR ROCK INC [US]); | [A]WO2019152895 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]); | [A]AU2020201807 (MOLECULAR TEMPLATES INC [US]) |